Evofem gains as study of gel in sexually transmitted infections nears end

Evofem Biosciences

01/08/2022 16:26

** Shares of Evofem Biosciences  EVFM.O  rise 2.8% to $0.75
    ** Co says last subject has completed last visit in
late-stage trial testing Phexxi for prevention of chlamydia and
gonorrhea infection in women  urn:newsml:reuters.com:*:nPn4ghGgPa
    ** Chlamydia and gonorrhea are both sexually transmitted
infections (STIs) caused by bacteria
    **  Phexxi is currently approved in the United States for
prevention of pregnancy
    ** Top-line readout of data expected in October; U.S.
regulatory submission planned for H1 2023
    ** About 1,579,885 cases of chlamydia and 677,769 cases of
gonorrhea were reported to U.S. CDC in 2020
    ** Stock down ~87% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))